Kuros Biosciences AG (0RHR.L)
CHF 20.55
(1.23%)
CHF 20.55
(1.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.84 Million | -7.34 Million | -5.45 Million | -9.23 Million | -10.84 Million | -12.83 Million |
| Net Income | -13.72 Million | -15.99 Million | -9.55 Million | -12.09 Million | -11.82 Million | -13.81 Million |
| Depreciation & Amortization | 2.75 Million | 2.83 Million | 2.88 Million | 2.66 Million | 2.71 Million | 1.94 Million |
| Deferred income taxes | -13.41 Million | - | 130 Thousand | -110 Thousand | -863 Thousand | -2.02 Million |
| Stock-based compensation | 917 Thousand | 1.03 Million | 389 Thousand | 752 Thousand | 498 Thousand | 675 Thousand |
| Change in working capital | -3.64 Million | -1.26 Million | -187 Thousand | -730 Thousand | -1.39 Million | 284 Thousand |
| Other non-cash items | 18.27 Million | 6.04 Million | 889 Thousand | 274 Thousand | 17 Thousand | 91 Thousand |
| Investing Cash Flow | -326 Thousand | -400 Thousand | -374 Thousand | -220 Thousand | -118 Thousand | -652 Thousand |
| Investments in PPE | -326 Thousand | -400 Thousand | -374 Thousand | -220 Thousand | -118 Thousand | -662 Thousand |
| Acquisitions | - | - | - | - | - | 10 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -9000.00 | -6000.00 | -70 Thousand | -159 Thousand | -33 Thousand | 10 Thousand |
| Financing Cash Flow | -171 Thousand | 3.22 Million | 6.07 Million | 17.07 Million | 13.12 Million | 15.01 Million |
| Debt repayment | -672 Thousand | -2.37 Million | -6.4 Million | -104 Thousand | -220 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 501 Thousand | 6 Million | - | 18.61 Million | 14.3 Million | 16.46 Million |
| Other Financing Activities | -672 Thousand | -402 Thousand | 12.47 Million | -1.43 Million | -957 Thousand | -1.45 Million |
| Accounts receivables | -4.57 Million | -1.64 Million | -737 Thousand | -375 Thousand | -476 Thousand | -284 Thousand |
| Accounts payables | 55 Thousand | 1.64 Million | 737 Thousand | 375 Thousand | 476 Thousand | - |
| Inventory | -2.47 Million | -1.58 Million | -340 Thousand | -516 Thousand | -469 Thousand | -337 Thousand |
| Other working capital | 3.34 Million | 319 Thousand | 153 Thousand | -214 Thousand | -923 Thousand | 621 Thousand |
| Cash at beginning of period | 24.06 Million | 28.62 Million | 28.38 Million | 20.8 Million | 18.33 Million | 16.67 Million |
| Cash at end of period | 14.2 Million | 24.06 Million | 28.62 Million | 28.38 Million | 20.8 Million | 18.33 Million |
| Capital Expenditure | -326 Thousand | -400 Thousand | -374 Thousand | -220 Thousand | -118 Thousand | -662 Thousand |
| Effect of forex changes on cash | -516 Thousand | -34 Thousand | -10 Thousand | -32 Thousand | 309 Thousand | 133 Thousand |
| Net cash flow / Change in cash | -9.85 Million | -4.55 Million | 241 Thousand | 7.58 Million | 2.46 Million | 1.66 Million |
| Free Cash Flow | -9.17 Million | -7.74 Million | -5.82 Million | -9.45 Million | -10.96 Million | -13.5 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -211 Thousand | -8.67 Million | -13.72 Million | -4.33 Million | -5.05 Million | -2.52 Million |
| Depreciation & Amortization | 1.27 Million | 1.33 Million | 2.75 Million | 661.5 Thousand | 1.41 Million | 690.5 Thousand |
| Deferred income taxes | - | - | -13.41 Million | - | -5.97 Million | 1.48 Million |
| Stock-based compensation | - | 400 Thousand | 917 Thousand | 400 Thousand | 58.5 Thousand | 58.5 Thousand |
| Change in working capital | -2.98 Million | -10 Thousand | -3.64 Million | 18 Thousand | -3.63 Million | -1.81 Million |
| Other non-cash items | 6.94 Million | 11.88 Million | 18.27 Million | 2.2 Million | 6.45 Million | 224 Thousand |
| Investing Cash Flow | -614 Thousand | -234 Thousand | -326 Thousand | -117 Thousand | -92 Thousand | -46 Thousand |
| Investments in PPE | -614 Thousand | -235 Thousand | -326 Thousand | -117.5 Thousand | -91 Thousand | -41 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 500.00 | -9000.00 | 500.00 | -5000.00 | -5000.00 |
| Financing Cash Flow | 528 Thousand | 138 Thousand | -171 Thousand | 69 Thousand | -309 Thousand | -154.5 Thousand |
| Debt repayment | - | - | -672 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 827 Thousand | 501 Thousand | 501 Thousand | - | - | - |
| Other Financing Activities | -299 Thousand | 69 Thousand | -672 Thousand | 69 Thousand | -154.5 Thousand | -154.5 Thousand |
| Accounts receivables | -2.85 Million | -2.9 Million | -4.57 Million | -1.45 Million | -1.67 Million | -836 Thousand |
| Accounts payables | 1.47 Million | 3.48 Million | 55 Thousand | - | - | - |
| Inventory | -1.41 Million | -1.05 Million | -2.47 Million | -528 Thousand | -1.42 Million | -710.5 Thousand |
| Other working capital | -190 Thousand | 457 Thousand | 3.34 Million | 1.99 Million | -546 Thousand | -273 Thousand |
| Cash at beginning of period | 14.2 Million | 16.86 Million | 24.06 Million | - | 24.06 Million | - |
| Cash at end of period | 14.27 Million | 14.2 Million | 14.2 Million | -1.32 Million | 16.86 Million | -3.6 Million |
| Capital Expenditure | -614 Thousand | -235 Thousand | -326 Thousand | -117.5 Thousand | -91 Thousand | -41 Thousand |
| Effect of forex changes on cash | - | -229.5 Thousand | -516 Thousand | -229.5 Thousand | -28.5 Thousand | -28.5 Thousand |
| Net cash flow / Change in cash | 69 Thousand | -2.65 Million | -9.85 Million | -1.32 Million | -7.2 Million | -3.6 Million |
| Free Cash Flow | -930 Thousand | -2.33 Million | -9.17 Million | -1.16 Million | -6.83 Million | -3.41 Million |
NNSCF
NEGXF
MCSHF
NBR
6843
FFSB